Skip to Main Content

Go to Main Navigation

Akston Biosciences Corporation

Company Type:
Small Business (1-10M TTM Revenue)

Therapeutics being developed using Akston’s platform technology are designed to seek out disease-causing biomolecules in the body and label them for destruction.

Using this technology, it has demonstrated in vivo the ability to bind and eliminate amyloid beta, a protein linked to the cause of Alzheimer’s Disease. In June 2014, the company was awarded a $249,926 NIH Phase I SBIR grant to support its work in this area.

The company has also applied its platform to certain autoimmune diseases where the therapeutic is designed to bind the autoantibodies and cells that attack healthy tissue and label them for destruction.

Site Badges
Akston Biosciences Corporation
100 Cummings Center Beverly, MA, 01915 United States

Get started

To request access, simply fill out the form below and we will contact you.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)

By signing up for this account you agree to the Terms of Service